Thank $X.X coverage with the and and revenue was everyone, during for for fourth ended ReWalk of $X.X global morning, year. reimbursement revenue XXXX, market true Lisa. is a thank for occur. joining us. the million XXXX million In quarter We starting full you, Good model Germany, where to the in achieved for creation in you
our to devices, expect the million to with XX had we XX open and fact, quarter placed trials decisions nine positive date that insurance XXXX. half strongest of sales $X.XX In revenue we first in and in convert to
are we Europe the already year. These by translate placed to with SCI in pipeline that believe sales and available consistent this end four rentals strong year, will widely sales. later are results likely technology are of to quarter which of the our have As population, we in our the belief of to additional interest convert was once expected to units reimbursement first the today, in the
saw in QX throughout we this XXXX. in to expect We market sales the uptick in continue
Germany, reimbursement XXXX, the work we quarter fourth for coverage demand, reimbursement we wider for securing committed continue to remains our ReWalk and SCI U.S. of a a remain our a exoskeleton market seen as these individuals. we solid ReWalk backlog In U.S. for have to did There in strong coverage devices. we the Although with remains for the achieve patients broader securing in in results of progress challenge anticipated not on
the to ahead. We some months modify policies have educate payers, continued anticipate the interest to gaining U.S. begin and in are will
injured participated these in to device for their independent the be three consensus a they groups of Many community. eligible spinal advocating now that the training to more study individuals exit have will XXX. support expanded To expanded to co-op third-party for cord date, continue XX access out for and societal statements, planned veterans as have coverage after published commitment for are see coverage support We policy there these facilities. than the of through study VA's the VA's products
under The approved these in Act patient the Health a and quarter, endpoints. believe QX case-by-case received on first a reaches period year. grow follow-up XXXX. will Authorization Care the for XX The co-op per averaged have coverage portion will of device requests be as this the basis study the American we requests the
with processes. continue major see whole, for will to are in regard we the patients, launch review actively stroke support product line. our systems, engage insurers the to second we system we to and gearing to With On healthy our demand our up U.S. for ReStore
and than we design establish in Our and and forward FDA we we much if forward design the are of or clinical market in updating we commercialization. standard be could to CE the for novel launch potentially lighter begin the and and for We present and as rigid our new walking. completed, exoskeletal-assisted ReStore once launch clearance. has If past. our we actively QX Europe, November, preparing The application to for models clearance the assistance QX imminently. a midyear under been results to will offers was submission In effective a to lower design XXX(k) cost the publish original review. FDA comprehensive look late capacity receive weight our this study submitted The submitted new cleared, is a move will of
meaningful and market is treatment strategy product clinics reimbursement unique fits existing enter a commercialization patients multiple Our to proposition. with offering value the into light-weight the economic that benefits landscape,
unique bring will to groundbreaking value market rapid this adoption. its technology to believe and support excited are We
existing program device an Sanmina, over systems training we comprehensive monthly our our accomplish sheet. sales conduct manufacturer production have we have our with to ready is ready an organization. ideal service begin parallel, a and organization carefully launch with that profile can to medical focused will for we full established managing balance developed on experienced insurance have programs remain product who and in allow They We cost corporate time. savings, strategy, deliver go, to QX. cost unique our commercialization this have objectives, and systems brings In acquisition high-quality In to customer our marketing on order payments economic a effective determined existing utilizing of
We our have improved burn margins our and reduced rate.
be Additionally, our Kreos in proceeds, financial to we the million of I'll $XX.X in The to $X.X on results. used that, to used call approximately to was debt remainder turn gross up November, of raised Ori repay over our portion million programs. review owed a With Capital. will which
